• AERO2.53+0.28 +12.44%
  • AGTK0.0129+0.0004 +3.2000%
  • AMMJ0.699-0.001 -0.143%
  • ATTBF0.0901-0.0098 -9.8098%
  • CANN1.45-0.02 -1.36%
  • CARA14.06-0.21 -1.47%
  • CBDS2.85-0.21 -6.86%
  • CGRW1.01+0.12 +13.48%
  • CNAB0.93-0.01 -1.06%
  • DIDG0.0001+0.0000 +0.0000%
  • EDXC0.039208-0.001702 -4.160359%
  • FULL2.67+0.00 +0.00%
  • GBLX0.257+0.000 +0.000%
  • GRNH0.059+0.003 +5.169%
  • GWPH102.45+0.13 +0.13%
  • HEMP0.0234-0.0031 -11.6981%
  • INCC0.0004+0.0000 +0.0000%
  • INSY9.27+0.02 +0.22%
  • LXRP0.3753-0.0247 -6.1750%
  • MCIG0.2222-0.0040 -1.7683%
  • MJNA0.1018+0.0018 +1.8000%
  • MJNE0.79-0.05 -5.84%
  • MNTR0.95+0.03 +3.26%
  • NDEV0.405+0.004 +0.998%
  • NTRR0.07275+0.00205 +2.89958%
  • OXIS0.0985+0.0135 +15.8824%
  • PMCB0.065+0.000 +0.000%
  • PLPL0.0142+0.0006 +4.4118%
  • RSSFF0.063+0.003 +5.000%
  • SPRWF0.8725-0.0128 -1.4436%
  • SRNA0.1118-0.0132 -10.5600%
  • STEV0.0022-0.0002 -8.4097%
  • TRTC0.252-0.006 -2.326%
  • TURV0.30+0.01 +1.69%
  • TWMJF6.9934-0.0566 -0.8028%
  • XXII2.18+0.04 +1.87%
  • ZDPY0.86-0.04 -4.44%
  • AUDUSD=X0.7857
  • USDJPY=X110.7400
To show stock chart
ChewingGumImagerMartialBACQUETViaWikimediaCommons

Cannabis Chewing Gum for Multiple Sclerosis in Development

AXIM Biotechnologies and its partner Quay Pharmaceuticals have obtained the necessary licenses to move forward with the development of a cannabis chewing gum, called MedChew Rx, for the treatment of multiple sclerosis (MS).  

MedChew Rx is being developed as a pharmaceutical drug to treat pain and spasticity associated with MS, according to a press release.

The gum consists of 5 mg of cannabidiol (CBD) and 5 mg of tetrahydrocannabinol (THC).

Read More at SpecialtyPharmacyTimes.com



CANNABIS ENTREPRENEURS
READ BLUNT

SIGN UP FOR FREE WEEKLY CANNABIS
BUSINESS NEWS, ANALYSIS AND ALERTS